New federal analyses show hospital takeovers of doctor offices and pharmacy steering are quietly adding fees and higher prices to patients’ bills.
Story Highlights
- Medicare’s own advisers say hospital ownership of clinics triggers extra “facility” fees that raise costs.
- Research links hospital-physician consolidation to higher prices for routine care.
- Pharmacy benefit manager integration can steer prescriptions to owned pharmacies, affecting what patients pay.
- Some federal economists see drug-price drops inside insurer–pharmacy manager combos, but not across the board.
What Vertical Integration Looks Like On Your Bill
Medicare’s advisory commission reports that when a hospital buys a clinician practice, the hospital can often bill a facility fee on top of the doctor’s fee. That stacked charge hits every visit at the now hospital-owned site, even if nothing about the care changed. Those site-based payment gaps turn a normal checkup into a higher-priced hospital outpatient claim, lifting what taxpayers and seniors cover through Medicare coinsurance.
Earlier Medicare advisory work found that when hospitals fold physician groups into their systems, prices for physician services rise in both commercial and Medicare markets. The mechanism is simple. Ownership changes where care is billed and at what rate schedule. The same test in a hospital outpatient department can cost far more than in an independent office. That price jump flows through to premiums, taxes, and patients’ out-of-pocket costs.
How Consolidation Steers Care And Prescriptions
Federal testimony explains that pharmacy benefit managers, when tied to insurers and specialty pharmacies, can steer prescriptions to their own pharmacies. That setup may also lead to higher internal reimbursements paid to affiliated pharmacies, shifting margin inside the same corporate family. Patients feel it as narrowed choice and complex bills. Policymakers have flagged these steering risks as a driver of specialty drug spending growth and confusion at the counter.
Medicare’s June 2026 report describes how big differences in payment across sites push care toward higher-paid settings. Those gaps create a financial pull that can overwhelm clinical need. Plans try to redirect care to lower-cost sites when allowed, but ownership links and local market power limit options. When one system controls the doctors, clinics, and hospital, referrals and scheduling often stay in-house, keeping dollars inside the system and prices above independent benchmarks.
What The Data Say About Prices, And The Narrow Exception
A broad body of research ties hospital mergers and hospital-physician integration to higher prices. Congressional and academic reviews report increases ranging from single digits to over thirty percent in some markets. These hikes show up without clear, consistent gains in quality. That is why watchdogs press for site-neutral payments, so similar services pay similar rates no matter the logo on the door, cutting the incentive to buy clinics just to bill more.
The Congressional Budget Office offers a narrow offset in the drug space. The office says when an insurer owns a pharmacy benefit manager, better-aligned incentives can lower the drug prices paid inside that integrated plan. But the same review warns that other types of mergers in the pharmacy chain can raise patient costs. In short, some vertical deals might trim prices within a plan, while many others push costs up across the market.
Why This Matters To Families And Taxpayers
Every extra facility fee and higher site rate lands on someone’s kitchen table. Seniors pay more coinsurance. Working families see higher premiums. Taxpayers fund bigger Medicare outlays. This is not about better care; it is about billing rules that reward ownership and location over value. Conservative reformers argue for clear, site-neutral payment and real transparency, so competition on price and service can beat boardroom games that load costs onto patients.
Lawmakers are weighing pharmacy benefit manager reforms and tougher merger reviews. Those steps aim to stop steering that limits choice and to block deals that raise prices. The goal should be simple: end payment loopholes, keep care close to home, and protect seniors’ fixed incomes. President Trump’s administration can press agencies to back site-neutral payment, police conflicts in pharmacy steering, and restore competition that puts patients and taxpayers first.
Sources:
aapm.org, medpac.gov, warren.senate.gov, congress.gov, sciencedirect.com, pharmacytimes.com
